223 related articles for article (PubMed ID: 36400016)
1. Engineered T cell therapy for viral and non-viral epithelial cancers.
Norberg SM; Hinrichs CS
Cancer Cell; 2023 Jan; 41(1):58-69. PubMed ID: 36400016
[TBL] [Abstract][Full Text] [Related]
2. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.
Shao W; Yao Y; Yang L; Li X; Ge T; Zheng Y; Zhu Q; Ge S; Gu X; Jia R; Song X; Zhuang A
Exp Hematol Oncol; 2024 Apr; 13(1):37. PubMed ID: 38570883
[TBL] [Abstract][Full Text] [Related]
3. Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics.
Kirouac DC; Zmurchok C; Morris D
NPJ Syst Biol Appl; 2024 Mar; 10(1):31. PubMed ID: 38499572
[TBL] [Abstract][Full Text] [Related]
4. The role of small molecules in cell and gene therapy.
Brayshaw LL; Martinez-Fleites C; Athanasopoulos T; Southgate T; Jespers L; Herring C
RSC Med Chem; 2021 Mar; 12(3):330-352. PubMed ID: 34046619
[TBL] [Abstract][Full Text] [Related]
5. Swiss army knife T cell: one T cell many tumor targets.
Berjis A; Muthumani D; Sheppard NC; June CH
Cell Res; 2024 Jan; 34(1):5-6. PubMed ID: 37666977
[No Abstract] [Full Text] [Related]
6. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.
Baulu E; Gardet C; Chuvin N; Depil S
Sci Adv; 2023 Feb; 9(7):eadf3700. PubMed ID: 36791198
[TBL] [Abstract][Full Text] [Related]
7. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
9. CAR immune cells: design principles, resistance and the next generation.
Labanieh L; Mackall CL
Nature; 2023 Feb; 614(7949):635-648. PubMed ID: 36813894
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes following CAR T cell therapy: what we know so far.
Cappell KM; Kochenderfer JN
Nat Rev Clin Oncol; 2023 Jun; 20(6):359-371. PubMed ID: 37055515
[TBL] [Abstract][Full Text] [Related]
11. Dynamics and specificities of T cells in cancer immunotherapy.
Oliveira G; Wu CJ
Nat Rev Cancer; 2023 May; 23(5):295-316. PubMed ID: 37046001
[TBL] [Abstract][Full Text] [Related]
12. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
de Visser KE; Joyce JA
Cancer Cell; 2023 Mar; 41(3):374-403. PubMed ID: 36917948
[TBL] [Abstract][Full Text] [Related]
13. Neoantigen-targeted CD8
Puig-Saus C; Sennino B; Peng S; Wang CL; Pan Z; Yuen B; Purandare B; An D; Quach BB; Nguyen D; Xia H; Jilani S; Shao K; McHugh C; Greer J; Peabody P; Nayak S; Hoover J; Said S; Jacoby K; Dalmas O; Foy SP; Conroy A; Yi MC; Shieh C; Lu W; Heeringa K; Ma Y; Chizari S; Pilling MJ; Ting M; Tunuguntla R; Sandoval S; Moot R; Hunter T; Zhao S; Saco JD; Perez-Garcilazo I; Medina E; Vega-Crespo A; Baselga-Carretero I; Abril-Rodriguez G; Cherry G; Wong DJ; Hundal J; Chmielowski B; Speiser DE; Bethune MT; Bao XR; Gros A; Griffith OL; Griffith M; Heath JR; Franzusoff A; Mandl SJ; Ribas A
Nature; 2023 Mar; 615(7953):697-704. PubMed ID: 36890230
[TBL] [Abstract][Full Text] [Related]
14. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder BJ; Kurtz DM; Alig SK; Frank MJ; Shukla N; Garofalo A; Macaulay CW; Shahrokh Esfahani M; Olsen MN; Hamilton J; Hosoya H; Hamilton M; Spiegel JY; Baird JH; Sugio T; Carleton M; Craig AFM; Younes SF; Sahaf B; Sheybani ND; Schroers-Martin JG; Liu CL; Oak JS; Jin MC; Beygi S; Hüttmann A; Hanoun C; Dührsen U; Westin JR; Khodadoust MS; Natkunam Y; Majzner RG; Mackall CL; Diehn M; Miklos DB; Alizadeh AA
Cancer Cell; 2023 Jan; 41(1):210-225.e5. PubMed ID: 36584673
[TBL] [Abstract][Full Text] [Related]
15. Multi-tiered approach to detect autoimmune cross-reactivity of therapeutic T cell receptors.
Ishii K; Davies JS; Sinkoe AL; Nguyen KA; Norberg SM; McIntosh CP; Kadakia T; Serna C; Rae Z; Kelly MC; Hinrichs CS
Sci Adv; 2023 Jul; 9(30):eadg9845. PubMed ID: 37494434
[TBL] [Abstract][Full Text] [Related]
16. Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors.
Neeser A; Ramasubramanian R; Wang C; Ma L
Immunooncol Technol; 2023 Sep; 19():100385. PubMed ID: 37483659
[TBL] [Abstract][Full Text] [Related]
17. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma.
Hu J; Sánchez-Rivera FJ; Wang Z; Johnson GN; Ho YJ; Ganesh K; Umeda S; Gan S; Mujal AM; Delconte RB; Hampton JP; Zhao H; Kottapalli S; de Stanchina E; Iacobuzio-Donahue CA; Pe'er D; Lowe SW; Sun JC; Massagué J
Nature; 2023 Apr; 616(7958):806-813. PubMed ID: 36991128
[TBL] [Abstract][Full Text] [Related]
18. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.
Flugel CL; Majzner RG; Krenciute G; Dotti G; Riddell SR; Wagner DL; Abou-El-Enein M
Nat Rev Clin Oncol; 2023 Jan; 20(1):49-62. PubMed ID: 36418477
[TBL] [Abstract][Full Text] [Related]
19. Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma.
Guerra P; Martini A; Pontisso P; Angeli P
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509293
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
